Nicotinic Acid 250mg

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

nicotinic acid, Quantity: 250 mg

Available from:

Alphapharm Pty Ltd

Pharmaceutical form:

Tablet, uncoated

Composition:

Excipient Ingredients: lactose monohydrate; magnesium stearate; maize starch; povidone; purified talc

Administration route:

Oral

Units in package:

200 tablets, 100 tablets

Class:

Medicine Registered

Prescription type:

(S3) Pharmacist Only Medicine

Therapeutic indications:

Nicotinic acid is an essential dietary constituent, the lack of which leads to the clinical condition known as pellagra, which is characterised by loss of appetite, lethargy, weakness, diarrhoea, dermatitis and mental changes. An erythematous eruption resembling sunburn first appears on the back of the hands. Other areas exposed to light are later involved and eventually the lesions may be more widespread. The cutaneous manifestations are characteristically symmetrical and may darken, desquamate and scar. Nicotinic acid has been approved for the treatment of hypercholesterolaemia and hypertriglyceridaemia. It should be used as adjunctive therapy in addition to diet and other measures. Nicotinic acid can also be used to treat Frederickson-Lees Levy hyperlipoproteinaemia type II, IIB, III, IV and V.

Product summary:

Visual Identification: White, bevelled edge tablet with breakline on one side; Container Type: Bottle; Container Material: Glass; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius

Authorization status:

Registered

Authorization date:

1991-10-21